Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$46.84 +4.2%	$23.26	$10.14 ▼ $56.83	$563.97M	0.79	129,756 shs	3.47 million shs
CGTX Cognition Therapeutics	$0.30 +15.6%	$0.33	$0.22 ▼ $2.54	$16.09M	0.75	2.73 million shs	1.52 million shs
IKNA Ikena Oncology	$1.37 +2.2%	$1.23	$0.97 ▼ $1.94	$64.67M	0.45	133,368 shs	33,767 shs
JATT JATT Acquisition	$1.12 -0.9%	$1.21	$7.80 ▼ $12.38	$19.32M	N/A	41,322 shs	328,513 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	+4.20%	+111.95%	+92.92%	+124.87%	+314.88%
CGTX Cognition Therapeutics	+15.61%	+7.14%	+1.04%	-32.07%	-83.78%
IKNA Ikena Oncology	+2.24%	+0.74%	+20.18%	+5.38%	-18.45%
JATT JATT Acquisition	-0.88%	-6.67%	+9.80%	-24.83%	-66.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDTX Cidara Therapeutics	3.7586 of 5 stars	3.6	2.0	0.0	4.6	3.1	0.0	0.0
CGTX Cognition Therapeutics	3.1105 of 5 stars	3.5	5.0	0.0	0.0	0.6	1.7	1.3
IKNA Ikena Oncology	3.6436 of 5 stars	3.3	5.0	0.0	0.0	3.6	1.7	1.3
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.11	Buy	$53.71	14.68% Upside
CGTX Cognition Therapeutics	3.00	Buy	$5.63	1,775.00% Upside
IKNA Ikena Oncology	2.50	Moderate Buy	$3.00	118.98% Upside
JATT JATT Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CDTX, CGTX, JATT, and IKNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00
6/10/2025	CDTX Cidara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/4/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
6/2/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$1.27M	462.87	N/A	N/A	$14.92 per share	3.14
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.31 per share	N/A
IKNA Ikena Oncology	$9.16M	7.22	N/A	N/A	$2.61 per share	0.52
JATT JATT Acquisition	N/A	N/A	$0.04 per share	27.08	($0.53) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
CGTX Cognition Therapeutics	-$33.97M	-$0.74	N/A	N/A	N/A	N/A	-194.42%	-115.14%	8/6/2025 (Estimated)
IKNA Ikena Oncology	-$49.23M	-$0.86	N/A	N/A	N/A	N/A	-30.59%	-27.55%	8/14/2025 (Estimated)
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A

Latest CDTX, CGTX, JATT, and IKNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	IKNA Ikena Oncology	-$0.21	-$0.18	+$0.03	-$0.18	N/A	N/A
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
IKNA Ikena Oncology	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	3.87	3.87
CGTX Cognition Therapeutics	N/A	2.09	2.09
IKNA Ikena Oncology	N/A	13.31	13.31
JATT JATT Acquisition	N/A	0.15	0.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
CGTX Cognition Therapeutics	43.35%
IKNA Ikena Oncology	75.00%
JATT JATT Acquisition	47.97%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	7.64%
CGTX Cognition Therapeutics	14.40%
IKNA Ikena Oncology	5.94%
JATT JATT Acquisition	20.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	12.55 million	11.59 million	No Data
CGTX Cognition Therapeutics	20	61.99 million	53.07 million	Not Optionable
IKNA Ikena Oncology	70	48.26 million	45.39 million	Not Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable

CDTX, CGTX, JATT, and IKNA Headlines

Recent News About These Companies

Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks

December 25, 2024 | markets.businessinsider.com

Zura Bio (ZURA) Receives a Buy from Piper Sandler

December 13, 2024 | markets.businessinsider.com

Cautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial Uncertainty

November 11, 2024 | markets.businessinsider.com

The Legend of Maula Jatt Review: Fawad Khan’s GoT-Coded War Epic Is Derivative, RIdden With Cliches

October 4, 2024 | moneycontrol.com

Release of Fawad Khan’s Pakistani blockbuster ‘The Legend of Maula Jatt’ halted in India

October 4, 2024 | thehindu.com

Pakistani hit The Legend of Maula Jatt, starring Fawad Khan, Mahira Khan, not to release in India, confirms distributor

October 4, 2024 | hindustantimes.com

India puts blockbuster Pakistani film on hold

October 4, 2024 | bbc.co.uk

"What is need to release Pakistani film in India?" Shiv Sena (UBT) opposes release of 'The Legend of Maula Jatt'

September 22, 2024 | malaysiasun.com

Shiv Sena (UBT) leader Anand Dubey opposes release of Pakistani film 'The Legend of Maula Jatt' in India

September 22, 2024 | malaysiasun.com

‘Jatt & Juliet 3’ OTT release: When and where to watch the Diljit Dosanjh and Neeru Bajwa starrer rom-com

August 27, 2024 | timesofindia.indiatimes.com

Bahdarpur Jatt Pin Code

April 10, 2024 | indiatvnews.com

Nishikant Dubey, wife booked in med college acquisition case

March 31, 2024 | timesofindia.indiatimes.com

Sen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. Steel

December 22, 2023 | pennlive.com

Microsoft poised to close massive Activision Blizzard acquisition next week

October 9, 2023 | vg247.com

The Legend of Maula Jatt to be released in cinemas on Thursday

July 8, 2023 | radio.gov.pk

Pakistani film The Legend of Maula Jatt reunites South Asian communities in Antwerp Belgium

June 15, 2023 | radio.gov.pk

Zura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% Upside

May 24, 2023 | msn.com

I Am A Jaat. People Often Confuse Me For A Jatt. Here’s The Difference Between The Two

April 28, 2023 | scoopwhoop.com

Zura Bio Announces Appointment of Chief Scientific Officer

April 16, 2023 | businesswire.com

TalkTalk, the Issa brothers and AO: The 19 latest deals from across the North West

March 30, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, CGTX, JATT, and IKNA Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

$46.84 +1.89 (+4.20%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$44.15 -2.69 (-5.74%)

As of 07:55 AM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cognition Therapeutics NASDAQ:CGTX

$0.30 +0.04 (+15.61%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$0.31 +0.01 (+4.00%)

As of 07:57 AM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Ikena Oncology NASDAQ:IKNA

$1.37 +0.03 (+2.24%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$1.41 +0.04 (+2.85%)

As of 04:11 AM Eastern

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

JATT Acquisition NYSE:JATT

$1.12 -0.01 (-0.88%)

As of 06/23/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time